Exploring Three High Growth Tech Stocks in the United States

In This Article:

The United States market has shown robust performance, climbing 2.2% in the last 7 days and an impressive 33% over the past year, with earnings projected to grow by 15% annually in the coming years. In such a dynamic environment, identifying high growth tech stocks involves focusing on companies that demonstrate strong innovation potential and adaptability to leverage these favorable conditions.

Top 10 High Growth Tech Companies In The United States

Name

Revenue Growth

Earnings Growth

Growth Rating

Super Micro Computer

23.83%

24.32%

★★★★★★

Bitdeer Technologies Group

37.45%

111.07%

★★★★★★

Sarepta Therapeutics

24.00%

42.88%

★★★★★★

Clene

78.50%

60.16%

★★★★★★

TG Therapeutics

34.66%

56.98%

★★★★★★

Alnylam Pharmaceuticals

22.45%

70.66%

★★★★★★

Alkami Technology

21.89%

98.60%

★★★★★★

Travere Therapeutics

31.70%

72.51%

★★★★★★

Seagen

22.57%

71.80%

★★★★★★

ImmunoGen

26.00%

45.85%

★★★★★★

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Zai Lab

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zai Lab Limited focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience with a market capitalization of approximately $2.60 billion.

Operations: Zai Lab generates revenue primarily from its biotechnology segment, amounting to $355.75 million. The company's focus spans oncology, autoimmune disorders, infectious diseases, and neuroscience therapies.

Zai Lab, amidst a challenging landscape for biotech firms, is navigating its path toward profitability with strategic agility and innovation. The company's recent collaboration with Pfizer to commercialize XACDURO in China exemplifies its strategic initiatives to enhance market presence and address critical health threats like carbapenem-resistant Acinetobacter baumannii. Financially, Zai Lab has demonstrated significant growth potential; its revenue is expected to surge by 34% annually, outpacing the US market's average of 8.9%. Moreover, earnings are projected to grow by an impressive 68.2% per year over the next three years as it transitions into profitability. This trajectory is supported by robust R&D investments that align with Zai Lab’s commitment to addressing unmet medical needs through advanced therapeutic solutions.

NasdaqGM:ZLAB Earnings and Revenue Growth as at Nov 2024
NasdaqGM:ZLAB Earnings and Revenue Growth as at Nov 2024

Pegasystems

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pegasystems Inc. is a company that develops, markets, licenses, hosts, and supports enterprise software across various regions including the United States, Europe, and Asia-Pacific with a market cap of approximately $7.85 billion.